Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations-Reference-Cited by-同舟云学术

Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations

Published:2012-07 Issue:7 Volume:11 Page:643-650
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Galpern Wendy R,Corrigan-Curay Jacqueline,Lang Anthony E,Kahn Jeffrey,Tagle Danilo,Barker Roger A,Freeman Thomas B,Goetz Christopher G,Kieburtz Karl,Kim Scott YH,Piantadosi Steven,Comstock Rick Amy,Federoff Howard J

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference53 articles.

1. Slowing the progression of Alzheimer disease: methodologic issues;Leber;Alzheimer Dis Assoc Disord,1997

2. A double-blind, delayed-start trial of rasagiline in Parkinson's disease;Olanow;N Engl J Med,2009

3. The powerful placebo;Beecher;J Am Med Assoc,1955

4. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease;de la Fuente-Fernandez;Science,2001

5. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial;McRae;Arch Gen Psychiatry,2004

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The history and status of dopamine cell therapies for Parkinson's disease;BioEssays;2024-07-26

2. Overcoming Methodological Challenges for Advancing Stem Cell Therapies in Parkinson’s Disease;Cell Transplantation;2024-01

3. Metabolic Networks in Parkinson’s Disease;Contemporary Clinical Neuroscience;2023

4. Estimating the sample size of sham-controlled randomized controlled trials using existing evidence;F1000Research;2022-11-07

5. Direct delivery of an investigational cell therapy in patients with Parkinson’s disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design;BMJ Neurology Open;2022-07